128
Views
8
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Golimumab for severe asthma

Evaluation: Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549-58

, MD PhD
Pages 1421-1423 | Published online: 14 Aug 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Christopher L. Grainge, Steven Maltby, Peter G. Gibson, Peter A. B. Wark & Vanessa M. McDonald. (2016) Targeted therapeutics for severe refractory asthma: monoclonal antibodies. Expert Review of Clinical Pharmacology 9:7, pages 927-941.
Read now

Articles from other publishers (7)

Tapan K Mukherjee, Parth Malik, Karl A Sanders & John R Hoidal. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine 314 319 .
Hideyasu Yamada, Norihito Hida, Yuko Kurashima, Hiroaki Satoh, Takefumi Saito & Nobuyuki Hizawa. (2019) A case of severe eosinophilic asthma and refractory rheumatoid arthritis well controlled by combination of IL-5Rα antibody and TNFα inhibitor. Allergology International 68:4, pages 536-538.
Crossref
Karen H. Calhoun. (2015) Asthma treatments: new and emerging therapies. International Forum of Allergy & Rhinology 5:S1, pages S76-S81.
Crossref
E. Bargagli, C. Olivieri & P. Rottoli. (2011) Cytokine modulators in the treatment of sarcoidosis. Rheumatology International 31:12, pages 1539-1544.
Crossref
Ines Zidi, Aicha Bouaziz, Wissem Mnif, Aghleb Bartegi & Nidhal Ben Amor. (2010) Golimumab and malignancies: true or false association?. Medical Oncology 28:2, pages 641-648.
Crossref
Joseph A. Jude, Reynold A. PanettieriJrJr, Timothy F. Walseth & Mathur S. Kannan. 2011. Advances in TNF Family Research. Advances in TNF Family Research 449 459 .
C. I. Daien, C. Lukas, B. Combe & J. Morel. (2010) Comment on: Sarcoid-like granulomatosis in patients treated with tumour necrosis factor blockers: 10 cases: reply. Rheumatology 49:5, pages 1021-1022.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.